Voices
Stephen V Liu: Long-Term Outcomes With Taletrectinib In ROS1 NSCLC
Stephen Liu/X

Stephen V Liu: Long-Term Outcomes With Taletrectinib In ROS1 NSCLC

Stephen V Liu,  Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:

“Long-term outcomes with taletrectinib in ROS1 NSCLC.

In 103 TKI naive pts with median f/u of 51m, RR 90.3%, DOR 49.7m, and PFS 49.6m. In 66 pts with prior crizotinib, RR 51.5%, DOR 13.2m, PFS 7.6m, OS 25.6m.”

Title: Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study

Authors: Wei Li, Yongchang Zhang, Huijie Fan, Qitao Yu, Feiwu Ran, Wenfeng Chen, Caicun Zhou

Read the Full Article on Journal of Clinical Oncology.

Stephen V Liu: Long-Term Outcomes With Taletrectinib In ROS1 NSCLC

Other Articles Featuring Stephen V Liu on OncoDaily.

Caicun Zhou cancer Feiwu Ran Huijie Fan Journal of Clinical Oncology Lung Cance NSCLC OncoDaily Oncology Qitao Yu Stephen V Liu Wei Li Wenfeng Chen Yongchang Zhang